Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma
Sponsor: Abramson Cancer Center at Penn Medicine
Listed as NCT01676831, this PHASE1/PHASE2 trial focuses on Cutaneous T Cell Lymphoma and remains completed. Sponsored by Abramson Cancer Center at Penn Medicine, it has been updated 11 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2023 — May 2023 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
Status: Unknown Status → Completed
-
Aug 2018 — Sep 2019 [monthly]
Unknown Status PHASE1_PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1_PHASE2
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Abramson Cancer Center at Penn Medicine
For direct contact, visit the study record on ClinicalTrials.gov .